Suppr超能文献

弥漫性大B细胞淋巴瘤患者诊断标本中EBV DNA载量和EBER状态的预后意义。

The prognostic significance of EBV DNA load and EBER status in diagnostic specimens from diffuse large B-cell lymphoma patients.

作者信息

Okamoto Akinao, Yanada Masamitsu, Inaguma Yoko, Tokuda Masutaka, Morishima Satoko, Kanie Tadaharu, Yamamoto Yukiya, Mizuta Shuichi, Akatsuka Yoshiki, Yoshikawa Tetsushi, Mizoguchi Yoshikazu, Nakamura Shigeo, Okamoto Masataka, Emi Nobuhiko

机构信息

Department of Hematology, Fujita Health University School of Medicine, Toyoake, Japan.

Department of Pediatrics, Fujita Health University School of Medicine, Toyoake, Japan.

出版信息

Hematol Oncol. 2017 Mar;35(1):87-93. doi: 10.1002/hon.2245. Epub 2015 Jul 14.

Abstract

Epstein-Barr virus (EBV)-encoded small RNA in situ hybridization (EBER-ISH) is a widely accepted method to evaluate EBV involvement in diffuse large B-cell lymphoma (DLBCL), although little is known regarding associations between EBV DNA load and the EBER status and whether EBV DNA load data provide additional clinical information. In this study, we quantified EBV DNA load in diagnostic specimens from DLBCL patients diagnosed at our hospital to evaluate clinical implications of EBV DNA load in diagnostic specimens as contrasted with EBER-ISH. Among 140 DLBCL patients without underlying immunodeficiency, 51 were evaluable for both EBER and EBV DNA load, 83 for EBER only and one for EBV DNA load only. The median EBV DNA load was 708 copies/µg. Although EBV DNA load was significantly higher for EBER-positive patients than for EBER-negative patients (p < 0.001), EBV DNA was detected in up to 72% of EBER-negative patients. Progression-free survival and overall survival were significantly worse for patients with EBV DNA load above 700 copies/µg than for those with EBV DNA load below 700 copies/µg (p = 0.009 and p = 0.003); they were also significantly worse for EBER-positive patients than for EBER-negative patients (p < 0.001 and p = 0.001). Even among EBER-negative patients, higher EBV DNA load conferred worse progression-free survival and overall survival (p = 0.041 and p = 0.013). These findings indicate that EBV DNA load in diagnostic specimens is not a simple surrogate for the EBER status and may be a potential biomarker associated with EBV involvement and prognosis in DLBCL. Copyright © 2015 John Wiley & Sons, Ltd.

摘要

爱泼斯坦-巴尔病毒(EBV)编码小RNA原位杂交(EBER-ISH)是评估EBV与弥漫性大B细胞淋巴瘤(DLBCL)关系的一种广泛接受的方法,尽管对于EBV DNA载量与EBER状态之间的关联以及EBV DNA载量数据是否能提供额外的临床信息知之甚少。在本研究中,我们对我院诊断的DLBCL患者诊断标本中的EBV DNA载量进行了定量,以评估诊断标本中EBV DNA载量与EBER-ISH相比的临床意义。在140例无基础免疫缺陷的DLBCL患者中,51例可同时评估EBER和EBV DNA载量,83例仅可评估EBER,1例仅可评估EBV DNA载量。EBV DNA载量中位数为708拷贝/μg。尽管EBER阳性患者的EBV DNA载量显著高于EBER阴性患者(p<0.001),但高达72%的EBER阴性患者检测到EBV DNA。EBV DNA载量高于700拷贝/μg的患者无进展生存期和总生存期显著差于EBV DNA载量低于700拷贝/μg的患者(p=0.009和p=0.003);EBER阳性患者的无进展生存期和总生存期也显著差于EBER阴性患者(p<0.001和p=0.001)。即使在EBER阴性患者中,较高的EBV DNA载量也会导致较差的无进展生存期和总生存期(p=0.041和p=0.013)。这些发现表明,诊断标本中的EBV DNA载量并非EBER状态的简单替代指标,可能是与DLBCL中EBV参与及预后相关的潜在生物标志物。版权所有©2015约翰威立父子有限公司。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验